Ibrutinib is a first-in-class oral Bruton's tyrosine kinase (BTK) inhibitor that selectively covalently binds to the cysteine residue (Cys-481) in the active site of the target protein Btk, irreversibly inhibits BTK, and effectively prevents tumors from migrating from the B-cells to lymphoid tissues adapted to the environment in which the tumor grows.Ibrutinib is used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).MCL and CLL are both B-cell non-Hodgkin's lymphomas, which are refractory and prone to relapse, and commonly used chemo-immunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur.Ibrutinib can bind to BTK targeting, which is necessary for B lymphocyte formation, differentiation, messaging and survival, and irreversibly inhibit the activity of BTK, effectively inhibiting the proliferation and survival of tumor cells; and it is rapidly absorbed after oral administration, reaching the maximum blood concentration in 1~2h, and the adverse reactions belong to grade 1 or 2, which would be a new choice for the treatment of CLL and MCL.